IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IOL Chemicals and Pharmaceuticals has submitted copies of newspaper publications of its Q1 FY26 (quarter ended 30 June 2025) unaudited financial results, as required under SEBI listing rules. The results were approved by the Board on 7 August 2025 and published in Financial Express, Economic Times, Business Standard, and Punjabi Jagran on 8 August 2025. Total income from operations stood at ₹559.06 crore, up from ₹509.76 crore in Q1 FY25, a growth of about 9.7% year-on-year. Net profit after tax rose to ₹33.96 crore (standalone) and ₹33.93 crore (consolidated), up roughly 14% from ₹29.68 crore / ₹29.97 crore in the same quarter last year. Basic and diluted EPS for the quarter was ₹1.16, compared to ₹1.02 in Q1 FY25. Statutory auditors issued an unmodified (clean) limited review opinion on the results.
This is a routine compliance filing confirming publication of already-approved quarterly results, with no new business action. The numbers themselves show healthy double-digit profit growth and steady revenue expansion, which is mildly positive for shareholders, though the stock has likely already priced in these results following the 7 August board approval.